Oramed Pharmaceuticals sell shadow
Start price
04.12.20
/
50%
€3.58
Target price
04.12.21
-
Performance (%)
282.12%
End price
05.12.21
€13.68
Summary
This prediction ended on 05.12.21 with a price of €13.68. The SELL prediction by shadow for Oramed Pharmaceuticals was trending in the completely wrong direction and closed with a performance of 282.12%. shadow has 50% into this predictionOramed is a pharmaceutical company that focuses on the development of innovative oral delivery solutions for drugs that are traditionally administered through injection. The company is primarily dedicated to the development of an oral insulin capsule that can potentially revolutionize the treatment of diabetes. Their flagship product, ORMD-0801, is currently in Phase III clinical trials in the United States and has received Fast Track designation from the FDA. Oramed is a publicly traded company listed on the Nasdaq under the ticker symbol ORMP.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Oramed Pharmaceuticals | 2.065% | 2.065% | 8.382% | -72.475% |
| iShares Core DAX® | 1.804% | -0.748% | 13.168% | 16.408% |
| iShares Nasdaq 100 | -0.182% | -3.412% | 39.976% | 43.502% |
| iShares Nikkei 225® | 0.413% | -7.381% | 18.776% | 2.874% |
| iShares S&P 500 | 0.664% | -1.941% | 28.141% | 42.155% |
According to shadow what are the pros and cons of Oramed Pharmaceuticals for the foreseeable future?
Pros
Cons
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Low dividend yield expected
negative Cash Flow expected
Bad rating
Little Investments for future growth
Risky balance sheet
Increased challenges to pay loans and raise capital
Below average Management
Bad culture
Little innovation
Few uniques
Dependend from some customers or products
Growths slower than the competition
Sustainability is little important
high free float
Higher risks for its business
Below average Marketposition
Significant cyclical dependencies
Little known brand
Business model of the past or high risk
Comments by shadow for this prediction
In the thread Oramed Pharmaceuticals diskutieren
Sell Oramed Pharmaceuticals
In the thread Trading Oramed Pharmaceuticals
Die von shadow gewählte maximale Laufzeit wurde überschritten